Literature DB >> 14630688

Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.

B Hellerstedt, A Ahmed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14630688     DOI： 10.1093/annonc/mdg488

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.

Authors:  Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

2.  Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Authors:  Alexandra M Levine; Ariela Noy; Jeannette Y Lee; Wayne Tam; Juan Carlos Ramos; David H Henry; Samir Parekh; Erin G Reid; Ronald Mitsuyasu; Timothy Cooley; Bruce J Dezube; Lee Ratner; Ethel Cesarman; Anil Tulpule
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Authors:  Raphaèle Seror; Christelle Sordet; Loic Guillevin; Eric Hachulla; Charles Masson; Marc Ittah; Sophie Candon; Véronique Le Guern; Achille Aouba; Jean Sibilia; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

4.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Authors:  J-E Gottenberg; L Guillevin; O Lambotte; B Combe; Y Allanore; A Cantagrel; C Larroche; M Soubrier; L Bouillet; M Dougados; O Fain; D Farge; X Kyndt; O Lortholary; C Masson; B Moura; P Remy; T Thomas; D Wendling; J-M Anaya; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2004-11-18       Impact factor: 19.103

5.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

6.  Is thymoglobulin or rituximab the cause of this serum sickness? A case report of serum sickness dilemma and literature review.

Authors:  Amarpreet Sandhu; Antonia Harford; Pooja Singh; Eduardo Alas
Journal:  Case Rep Med       Date:  2012-09-27

Review 7.  Cutaneous primary B-cell lymphomas: from diagnosis to treatment.

Authors:  Margarida Lima
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

Review 8.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

9.  GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption.

Authors:  Waseem Bakkour; Ian H Coulson
Journal:  Dermatol Ther (Heidelb)       Date:  2012-03-30

10.  Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.

Authors:  Shoko Goto; Hiroaki Goto; Reo Tanoshima; Hiromi Kato; Hiroyuki Takahashi; Osamu Sekiguchi; Sumio Kai
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.